JP2016517871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517871A5 JP2016517871A5 JP2016511009A JP2016511009A JP2016517871A5 JP 2016517871 A5 JP2016517871 A5 JP 2016517871A5 JP 2016511009 A JP2016511009 A JP 2016511009A JP 2016511009 A JP2016511009 A JP 2016511009A JP 2016517871 A5 JP2016517871 A5 JP 2016517871A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- cancer
- methyloctahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- -1 mono- substituted benzyl Chemical group 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165707.4 | 2013-04-29 | ||
| EP13165707 | 2013-04-29 | ||
| PCT/EP2014/058262 WO2014177441A1 (en) | 2013-04-29 | 2014-04-23 | New morpholinyl anthracycline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517871A JP2016517871A (ja) | 2016-06-20 |
| JP2016517871A5 true JP2016517871A5 (enExample) | 2017-06-08 |
Family
ID=48190306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511009A Pending JP2016517871A (ja) | 2013-04-29 | 2014-04-23 | 新規モルホリニルアントラサイクリン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9828405B2 (enExample) |
| EP (1) | EP2991993B1 (enExample) |
| JP (1) | JP2016517871A (enExample) |
| CN (1) | CN105164138B (enExample) |
| DK (1) | DK2991993T3 (enExample) |
| ES (1) | ES2695162T3 (enExample) |
| RU (1) | RU2666356C2 (enExample) |
| WO (1) | WO2014177441A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6785780B2 (ja) * | 2014-11-05 | 2020-11-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 官能基化モルホリニルアントラサイクリン誘導体 |
| CN108864221B (zh) * | 2018-06-08 | 2022-04-01 | 中国科学院上海有机化学研究所 | 阿克拉霉素类似物及其制法和用途 |
| CN110776501B (zh) * | 2019-08-22 | 2021-04-02 | 联宁（苏州）生物制药有限公司 | 一种用于抗体药物偶联物的药物毒素pnu-159682的制备方法及其中间体 |
| CN115043895A (zh) * | 2022-07-15 | 2022-09-13 | 戊言医药科技（上海）有限公司 | 一种pnu-159682及其中间体的制备方法 |
| CN115651043A (zh) * | 2022-10-27 | 2023-01-31 | 戊言医药科技（上海）有限公司 | 一种蒽环类毒素衍生物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3803124A (en) | 1968-04-12 | 1974-04-09 | Farmaceutici It Soc | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives |
| GB1511680A (en) * | 1975-11-18 | 1978-05-24 | Farmaceutici Italia | Daunosaminyl anthracyclinones |
| US4133877A (en) | 1976-07-08 | 1979-01-09 | Societa Farmaceutici Italia S.P.A. | Anthracycline ethers and use therefor |
| NZ224252A (en) | 1987-04-21 | 1991-09-25 | Erba Carlo Spa | An anthracycline glycoside and its preparation |
| GB8804429D0 (en) | 1988-02-25 | 1988-03-23 | Erba Carlo Spa | New 4-demethyl-4-0-(fluorobenzensulfonyl)anthracycline glycosides |
| GB2225781A (en) | 1988-05-13 | 1990-06-13 | Erba Carlo Spa | 10-Noranthracyclines |
| GB8902709D0 (en) | 1989-02-07 | 1989-03-30 | Erba Carlo Spa | New 4'-epi-4'-amino anthracyclines |
| GB8905668D0 (en) * | 1989-03-13 | 1989-04-26 | Erba Carlo Spa | New 3'-(4-morpholinyl)-and 3'-(2-methoxy-4-morpholinyl)-anthracycline derivatives |
| RU2081878C1 (ru) * | 1989-03-13 | 1997-06-20 | Фармиталиа Карло Эрба С.Р.Л. | Антрациклин гликозид и способ его получения |
| EP0434960B1 (en) | 1989-12-19 | 1996-09-18 | PHARMACIA S.p.A. | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates |
| GB9019933D0 (en) * | 1990-09-12 | 1990-10-24 | Erba Carlo Spa | 13-dihydro-3'-(2-alkoxy-4-morphlinyl)anthracyclines |
| GB2296495B (en) * | 1994-12-23 | 1998-04-15 | Erba Carlo Spa | Anthracycline derivatives |
| GB2315067B (en) * | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| FR2856687B1 (fr) * | 2003-06-25 | 2005-09-16 | Servier Lab | Nouveaux derives de benzo[a]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| MX2011000509A (es) * | 2008-07-15 | 2011-04-05 | Genentech Inc | Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales. |
| KR101897307B1 (ko) | 2010-12-02 | 2018-09-10 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 모르폴리닐 안트라사이클린 유도체의 제조 방법 |
-
2014
- 2014-04-23 RU RU2015150994A patent/RU2666356C2/ru active
- 2014-04-23 WO PCT/EP2014/058262 patent/WO2014177441A1/en not_active Ceased
- 2014-04-23 CN CN201480023999.XA patent/CN105164138B/zh not_active Expired - Fee Related
- 2014-04-23 JP JP2016511009A patent/JP2016517871A/ja active Pending
- 2014-04-23 EP EP14719005.2A patent/EP2991993B1/en active Active
- 2014-04-23 ES ES14719005T patent/ES2695162T3/es active Active
- 2014-04-23 DK DK14719005.2T patent/DK2991993T3/en active
- 2014-04-23 US US14/787,667 patent/US9828405B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012082234A5 (enExample) | ||
| JP2016517871A5 (enExample) | ||
| JP2016510028A5 (enExample) | ||
| JP2018516917A5 (enExample) | ||
| IL286846B1 (en) | History of Camptothecin | |
| JP2008505167A5 (enExample) | ||
| NZ597252A (en) | Compounds for inhibiting mitotic progression | |
| EA201391324A1 (ru) | Бис(фторалкил)-1,4-бензодиазепиноновые соединения | |
| MX2014013367A (es) | Composiciones organicas para tratar enfermedades relacionadas con kras. | |
| PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
| DOP2011000057A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| CY1119844T1 (el) | 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων | |
| NZ628298A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2016516702A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| NZ718826A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| JP2019512474A5 (enExample) | ||
| CA2649549A1 (en) | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds | |
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| CL2011001313A1 (es) | Compuestos derivados de n-(fenil)-sulfonilamina, inhibidores de bcl2 o bcl-xl; composicion farmaceutica; y su uso en el tratamiento de cancer de vejiga, cerebro, mamas, medula osea, cervical, colorrectal, esofago, cancer hepatocelular, leucemia linfoblastica, linfoma folicular, mieloma. | |
| NZ700583A (en) | Novel 7-deazapurine nucleosides for therapeutic uses | |
| WO2015118030A3 (en) | Antibody-drug conjugates and immunotoxins | |
| NZ711038A (en) | Tricyclic inhibitors of atr | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. |